TO LICENSE AGREEMENT. This Amendment No. 1 (“Amendment No. 1”) amends that certain License Agreement effective March 28, 2002 (the “Agreement”) entered by and between Maxygen, Inc. (“MUS”) and Codexis, Inc. (“Codexis”), and shall be effective as of September 13, 2002 (the “Amendment Date”). MUS and Codexis hereby amend the License Agreement as follows:
TO LICENSE AGREEMENT. This Amendment No. 4 to the License Agreement (“Amendment”), having an effective date of February 7, 2022 (“Amendment Effective Date”), is made and entered by and between Ohio State Innovation Foundation, located at 1524 North High Streex, Xxxxxxxx, Xxxx 00000 (“XXXX”) xxx Xxxxxxx Thxxxxeutics, Inc. located at 6 Tide Street, Boston, XX 00000 (“Xxxxxxxx”), (xxxxxidually “Party” or together “the Parties”).
TO LICENSE AGREEMENT. This AMENDMENT NO. 1 to LICENSE AGREEMENT (this “Amendment”) is made and entered into effective as of December 27, 2013 (the “Amendment Effective Date”), by and between Xxxxx Therapeutics, Inc., a Delaware corporation with offices at 0000 Xxxxxxxx Xxxxxx, Suite 100, Austin, Texas 78744 (“MirnaRx”), and Marina Biotech, Inc., a Delaware corporation with offices at 0000 Xxxxx Xxxxx Parkway, Bothell, Washington 98021 (“Marina Bio”).
TO LICENSE AGREEMENT. LICENSE OPERATING COMMITTEE SHAS Xxxx Xxxxxx Xxxxxxx Xxxxxxx Guy Xxxx Xxxxx Xxxxxxx Xxxxx Xxxx Xxxxxx Xxxxx Xxxx
TO LICENSE AGREEMENT. THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT (the “Amendment”) is made as of the ___ day of October 2000 by and between BENTLEY PHARMACEUTICALS, INC., a Delaware corporation with offices at 60 Xxxxxxxxx Xxxx, Xxxxx Xxxxx, Xxxxx Xxxxxxx, Xxx Xxxxxxxxx 03862-2403 (hereinafter “Bentley” or “Licensor”) and AUXILIUM A2 , INC., a Delaware corporation with offices at 160 W. Germantown Pike, Suite D-5, Norriton Office Center, Nxxxxxxxxx, Xxxxxxxxxxxx 00000 (hereafter, “Auxilium” or “Licensee”). Bentley and Auxilium may be referred to as a “Party” or, collectively, as “Parties.”
TO LICENSE AGREEMENT. This Amendment No. 3 (“Amendment No. 3”) amends that certain License Agreement effective March 28, 2002 entered by and between Maxygen, Inc. (“MUS”) and Codexis, Inc. (“Codexis”), as previously amended by Amendment No. 1 to License Agreement effective September 13, 2002, and Amendment Xx. 0 xx Xxxxxxx Xxxxxxxxx xxxxxxxxx Xxxxxxx 0, 0000, (xx amended, the “Agreement”), and shall be effective as of August , 2006 (the “Third Amendment Date”). MUS and Codexis hereby amend the Agreement as follows:
TO LICENSE AGREEMENT. This Amendment No. 1 to License Agreement (this “Amendment”) is made and entered into as of February 2, 2016 (the “Amendment Date”), and amends that certain License Agreement, dated as of July 16, 2014, as amended or supplemented through the Amendment Date (the “License Agreement”), by and between Caribou Biosciences, Inc. (“Caribou”) and Intellia Therapeutics, Inc. (“Intellia”) (as successor in interest to Intellia, LLC under the License Agreement). Each of Caribou and Intellia may be referred to herein as a “Party” or together as “Parties.” Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement.
TO LICENSE AGREEMENT. This Amendment No. 1 is an amendment to the License Agreement (the “License Agreement”) by and between TissueLink Medical, Inc., formerly named Virtuel Medical Devices, Inc. (“Licensee”), and Medtronic, Inc. (“Medtronic”) dated as of August 9, 1999. This Amendment No. 1 is dated as of June 18, 2002. All capitalized terms not defined in this Amendment No. 1 shall have the meanings set forth in the License Agreement. The parties hereby agree that the License Agreement is amended as follows:
TO LICENSE AGREEMENT. Amendment No.1 made and effective as of November 12, 2009 to the License Agreement dated November 1, 2005 entered into by and between Health Research, Inc., a New York corporation, with a principal place of business at Xxx & Xxxxxxx Xxxxxxx, Xxxxxxx, Xxx Xxxx 00000 (“HRI”) and ROSWELL PARK CANCER INSTITUTE (“Roswell”), with a place of business at Carlton and Xxx Xxxxxxx, Xxxxxxx, Xxx Xxxx 00000 (HRI and Roswell are collectively referred to as “Licensor”) and TRACON Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware with offices at 0000 Xxxxxxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx, Xxxxxxxxxx 00000 (“Company”).
TO LICENSE AGREEMENT. BETWEEN: ALZA Corporation, a Delaware corporation having a place of business at 000 Xxxxxxx Xxxxx, Vacaville, CA 95688, hereinafter also referred to as “Licensee”, AND: Pharmaceutical Product Development, Inc., a North Carolina corporation having a place of business at 000 Xxxxx Xxxxx Xxxxxx, Xxxxxxxxxx, XX 00000-0000 (hereinafter “PPD”) and its wholly based subsidiary GenuPro, Inc., d/b/a PPD GenuPro, a North Carolina corporation having a place of business at 0000 Xxxxxxxxx Xxxxxxx, Xxxxxxxxxxx, XX 00000 (hereinafter “GenuPro”). All above parties shall be collectively referred to as the “Parties” and individually as “Party”. PPD, GenuPro and Licensee have entered into an agreement with an Effective Date of January 2, 2001 and which was amended on December 26, 2003 by Amendment No. 1 to License Agreement (hereinafter collectively referred to as “License Agreement”) relating to the development and commercialization of dapoxetine. PPD, GenuPro and Licensee agree to amend the License Agreement as follows: Delete original Section 10.02 and insert new Section 10.02 as follows:
